Table 4.
Patient Characteristics by Treatment Outcome
| Characteristic | Total No. (Column %) |
Success | Died | Treatment Failed |
Lost to Follow-up | P Value |
|---|---|---|---|---|---|---|
| No. (Row %) | ||||||
| Total | 568 (82.8) | 84 (12.2) | 18 (2.6) | 16 (2.3) | … | |
| Age, y (n = 686) | <.01 | |||||
| <45 | 224 (32.7) | 206 (92.0) | 9 (4.0) | 6 (2.7) | 3 (1.3) | |
| 45–64 | 294 (42.9) | 254 (86.4) | 26 (8.8) | 7 (2.4) | 7 (2.4) | |
| ≥65 | 168 (24.5) | 108 (64.3) | 49 (29.2) | 5 (3.0) | 6 (3.6) | |
| Sex (n = 686) | .65 | |||||
| Female | 186 (27.1) | 153 (82.3) | 26 (14.0) | 3 (1.6) | 4 (2.2) | |
| Male | 500 (72.9) | 415 (83.0) | 58 (11.6) | 15 (3.0) | 12 (2.4) | |
| BMI, kg/m2 (n = 685) | .09 | |||||
| <18.5 | 143 (20.9) | 108 (75.5) | 28 (20.0) | 4 (2.8) | 3 (2.1) | |
| 18.5–23.9 | 394 (57.5) | 335 (85.0) | 38 (9.6) | 12 (3.1) | 9 (2.3) | |
| ≥24 | 148 (21.6) | 125 (84.5) | 17 (11.5) | 2 (1.4) | 4 (2.7) | |
| Smear (n = 686) | .04 | |||||
| Negative | 354 (51.6) | 287 (81.1) | 54 (15.3) | 7 (2.0) | 6 (1.7) | |
| Positive | 332 (48.4) | 281 (84.6) | 30 (9.0) | 11 (3.3) | 10 (3.0) | |
| Cavitary lesions (n = 686) | .29 | |||||
| No | 441 (64.3) | 361 (81.9) | 61 (13.8) | 10 (2.3) | 9 (2.0) | |
| Yes | 245 (35.7) | 207 (84.5) | 23 (9.4) | 8 (3.3) | 7 (2.9) | |
| Alcohol use (n = 686) | .14 | |||||
| No | 587 (85.6) | 479 (81.6) | 75 (12.8) | 18 (3.1) | 15 (2.6) | |
| Yes | 99 (14.4) | 89 (89.9) | 9 (9.1) | 0 (0) | 1 (1.0) | |
| Diabetes (n = 686) | .51 | |||||
| No | 450 (65.6) | 379 (84.2) | 50 (11.1) | 12 (2.7) | 9 (2.0) | |
| Yes | 236 (34.4) | 189 (80.1) | 34 (14.4) | 6 (2.5) | 7 (3.0) | |
| Cancer (n = 684) | <.01 | |||||
| No | 643 (94.0) | 550 (85.5) | 61 (9.5) | 17 (2.6) | 15 (2.3) | |
| Yes | 41 (6.0) | 17 (41.5) | 22 (53.7) | 1 (2.4) | 1 (2.4) | |
| Chronic kidney disease (n = 680) | <.01 | |||||
| No | 634 (93.2) | 538 (84.9) | 67 (10.6) | 15 (2.4) | 14 (2.2) | |
| Yes | 46 (6.7) | 27 (58.7) | 14 (30.4) | 3 (6.5) | 2 (4.4) | |
| Liver disease (n = 679) | .68 | |||||
| No | 582 (85.7) | 487 (83.7) | 69 (11.3) | 16 (2.8) | 13 (2.2) | |
| Yes | 97 (14.3) | 77 (79.4) | 15 (15.5) | 2 (2.1) | 3 (3.1) | |
| Hypertension (n = 686) | <.01 | |||||
| No | 524 (76.4) | 446 (85.1) | 50 (9.5) | 15 (2.9) | 13 (2.5) | |
| Yes | 162 (23.6) | 122 (75.3) | 34 (21.0) | 3 (1.9) | 3 (1.9) | |
| Cardiovascular disease (n = 680) | <.01 | |||||
| No | 622 (91.5) | 525 (84.4) | 66 (10.6) | 17 (2.7) | 14 (2.3) | |
| Yes | 58 (8.5) | 40 (69.0) | 15 (25.9) | 1 (1.7) | 2 (3.5) | |
| History of anti-TB treatment | .05 | |||||
| No | 309 (45.1) | 258 (83.5) | 44 (14.2) | 4 (1.3) | 3 (1.0) | |
| First-line drugs | 324 (47.2) | 269 (83.0) | 34 (10.5) | 11 (3.4) | 10 (3.1) | |
| Second-line drugs | 53 (7.7) | 41 (77.4) | 6 (11.3) | 3 (5.7) | 3 (5.7) | |
| Type of case registration | .03 | |||||
| New | 351 (51.2) | 293 (83.5) | 48 (13.7) | 7 (2.0) | 3 (0.9) | |
| Retreatment | 335 (48.8) | 275 (82.1) | 36 (10.8) | 11 (3.3) | 13 (3.9) | |
| Relapse | 189 (27.6) | 157 (83.1) | 21 (11.1) | 5 (2.7) | 6 (3.2) | |
| Treatment after loss to follow-up | 17 (2.5) | 14 (82.4) | 1 (5.9) | 0 (0) | 2 (11.8) | |
| Treatment after treatment failure | 129 (18.8) | 104 (80.6) | 14 (10.9) | 6 (4.7) | 5 (3.9) | |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; TB, tuberculosis.